Objective: Regional Homogeneity (ReHo) measures the local coherence of spontaneous brain activity, and it is sensitive to detect aberrant local functional connectivity of brain region. We tried to explore the activity of brain network by ReHo method in amnestic mild cognitive impairment (aMCI) patients and examine the impact of regional brain atrophy on the functional results.
Methods: Data of both structural magnetic resonance images (MRI) and resting-state functional MRI scans were collected from 36 aMCI patients and 46 age-matched healthy controls.
Results: Compared with the HC subjects, the aMCI patients showed significant decreased ReHo areas in the right inferior parietal lobule (IPL), left posterior cingulate cortex/precuneus (PCC/PCu), left inferior temporal gyrus (ITG), right supramarginal gyrus (SMG), right fusiform gyrus (FG), bilateral lentiform nucleus (LN) and right cerebellum posterior lobe, with the right IPL being the most significant area. In addition, the aMCI group also had some significant increased ReHo areas in the right medial frontal gyrus (MFG), bilateral postcentral gyrus (PoCG), left cuneus and right lingual gyrus (LG), possibly reflective of some underlining compensatory mechanism. Furthermore, in the aMCI patients, we found the ReHo index of the left PCC was positively correlated with the AVLT-Immediate Recall scores, while the ReHo index of the left cuneus was negatively correlated with the MMSE scores. In addition, we found that after regressing out the identified regional brain atrophy, the significant correlations between fitted ReHo index and clinical variables still remained.
Conclusions: Our study indicated that aMCI patients showed significant abnormal local coherence of biological activity in resting state and ReHo could serve as a sensitive biomarker in functional imaging studies of aMCI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neulet.2016.06.047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dysregulation of the molecular clock by blood-borne factors in Alzheimer's disease patients.
J Neurol
January 2025
Department of Central laboratory, Xuanwu Hospital of Capital Medical University, Beijing, 100053, P.R. China.
Background: Circadian disruptions are increasingly recognized in Alzheimer's disease (AD) patients and may influence disease onset and progression. This study examines how AD pathology affects blood-borne factors that regulate circadian rhythms.
Methods: Eighty-five participants from the Sino Longitudinal Study on Cognitive Decline were enrolled: 35 amyloid-beta negative normal controls (Aβ- NCs), 23 amyloid-beta positive normal controls (Aβ+ NCs), 15 patients with amnestic mild cognitive impairment (aMCI), and 12 with Alzheimer's disease dementia (ADD).
The investigation of peripheral inflammatory and oxidative stress biomarkers in dementia with Lewy Bodies, compared with Alzheimer's Disease, and mild cognitive impairment.
Neuroscience
January 2025
Departments of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Electronic address:
Although inflammation and oxidative stress have been increasingly recognised as components of Alzheimer's disease (AD) and Parkinson's disease (PD) pathologies. Few studies have investigated peripheral inflammation, and none have examined oxidative stress in Dementia with Lewy bodies (DLB). The purpose of our study was to characterize and compare those biomarkers in DLB with those in AD and amnestic mild cognitive impairment (aMCI).
View Article and Find Full Text PDFSex differences in mitochondrial free-carnitine levels in subjects at-risk and with Alzheimer's disease in two independent study cohorts.
Mol Psychiatry
January 2025
Department of Psychiatry, New York University Grossman School of Medicine, New York, NY, USA.
A major challenge in the development of more effective therapeutic strategies for Alzheimer's disease (AD) is the identification of molecular mechanisms linked to specific pathophysiological features of the disease. Importantly AD has a two-fold higher incidence in women than men and a protracted prodromal phase characterized by amnestic mild-cognitive impairment (aMCI) suggesting that biological processes occurring early can initiate vulnerability to AD. Here, we used a sample of 125 subjects from two independent study cohorts to determine the levels in plasma (the most accessible specimen) of two essential mitochondrial markers acetyl-L-carnitine (LAC) and its derivative free-carnitine motivated by a mechanistic model in rodents in which targeting mitochondrial metabolism of LAC leads to the amelioration of cognitive function and boosts epigenetic mechanisms of gene expression.
View Article and Find Full Text PDFIntroduction: Hippocampal hyperactivity is a hallmark of prodromal Alzheimer's disease (AD) that predicts progression in patients with amnestic mild cognitive impairment (aMCI). AGB101 is an extended-release formulation of levetiracetam in the dose range previously demonstrated to normalize hippocampal activity and improve cognitive performance in aMCI. The HOPE4MCI study was a 78-week trial to assess the progression of MCI due to AD.
View Article and Find Full Text PDFLongitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment.
Alzheimers Dement
December 2024
Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven, Belgium.
Introduction: The longitudinal progression of synaptic loss in Alzheimer's disease (AD) and how it is affected by tau pathology remains poorly understood.
Methods: Thirty patients with amnestic mild cognitive impairment (aMCI) and 26 healthy controls underwent cognitive evaluations and tau, synaptic vesicle protein 2A (SV2A), and amyloid positron emission tomography. Twenty-one aMCI underwent 2-year follow-up (FU) investigations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!